We selected seven drugs including conventional chemotherapeutic drugs and inhibitors that target epigenetic regulator, canonical cancer-related pathways (NF-κB, Hippo, MAPK, and PI3K), and established cell culture and CI (combination index) value assay11 to screen for the effective combination therapies in the BETi-resistant cells (Fig. 1a, b and Supplementary Fig. 2). This evidence concerns the gene NFKB1 and cancer.